T. Rowe Price Health Sciences Fund, Inc.
Fund
PRHSX
Price as of:
$90.57
- $1.47
- 1.60%
Primary Theme
fund company
Name
As of 07/10/2026Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
8.4%
1 yr return
31.1%
3 Yr Avg Return
10.6%
5 Yr Avg Return
3.9%
Net Assets
$11.1 B
Holdings in Top 10
39.4%
52 WEEK LOW AND HIGH
$92.0
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 0.68%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 33.80%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$2,500
IRA
$1,000
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 07/10/2026Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
PRHSX - Profile
Distributions
- YTD Total Return 8.4%
- 3 Yr Annualized Total Return 10.6%
- 5 Yr Annualized Total Return 3.9%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.21%
- Dividend Yield 0.1%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameT. Rowe Price Health Sciences Fund, Inc.
-
Fund Family NameT. Rowe Price
-
Inception DateDec 29, 1995
-
Shares OutstandingN/A
-
Share ClassOther
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerZiad Bakri
Fund Description
In the Summary Prospectus, and Sections 1 and 2 of the Prospectus, the disclosure under “Principal Investment Strategies” is supplemented as follows:
The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.
PRHSX - Performance
Return Ranking - Trailing
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 8.4% | -22.9% | 47.0% | 35.29% |
| 1 Yr | 31.1% | -18.8% | 171.0% | 40.52% |
| 3 Yr | 10.6%* | -5.0% | 32.9% | 41.18% |
| 5 Yr | 3.9%* | -13.5% | 14.8% | 60.14% |
| 10 Yr | 10.7%* | 3.7% | 15.1% | 23.97% |
* Annualized
Return Ranking - Calendar
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2025 | 5.0% | -21.9% | 61.0% | 81.70% |
| 2024 | -9.5% | -28.2% | 17.1% | 90.20% |
| 2023 | -2.1% | -8.6% | 19.0% | 83.01% |
| 2022 | -13.7% | -53.9% | 3.2% | 68.24% |
| 2021 | 5.3% | -39.6% | 24.2% | 31.76% |
Total Return Ranking - Trailing
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 8.4% | -22.9% | 47.0% | 35.29% |
| 1 Yr | 31.1% | -18.8% | 171.0% | 40.52% |
| 3 Yr | 10.6%* | -5.0% | 32.9% | 41.18% |
| 5 Yr | 3.9%* | -13.5% | 14.8% | 60.14% |
| 10 Yr | 10.7%* | 3.7% | 15.1% | 23.97% |
* Annualized
Total Return Ranking - Calendar
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2025 | 17.7% | -0.5% | 63.7% | 45.75% |
| 2024 | 1.8% | -28.2% | 17.3% | 59.48% |
| 2023 | 3.1% | -8.6% | 19.0% | 72.55% |
| 2022 | -12.2% | -53.9% | 3.7% | 64.86% |
| 2021 | 13.3% | -33.9% | 26.0% | 31.08% |
NAV & Total Return History
PRHSX - Holdings
Concentration Analysis
| PRHSX | Category Low | Category High | PRHSX % Rank | |
|---|---|---|---|---|
| Net Assets | 11.1 B | 8.15 M | 38.2 B | 3.92% |
| Number of Holdings | 287 | 24 | 416 | 3.27% |
| Net Assets in Top 10 | 4.29 B | 3.06 M | 22.8 B | 4.58% |
| Weighting of Top 10 | 39.42% | 17.1% | 79.4% | 73.86% |
Top 10 Holdings
- ELI LILLY CO 10.14%
- THERMO FISHER SCIENTIFIC INC 4.07%
- INTUITIVE SURGICAL INC 3.65%
- STRYKER CORP 3.46%
- MERCK CO INC 3.44%
- ASTRAZENECA PLC 3.17%
- UNITEDHEALTH GROUP INC 3.09%
- ARGENX SE 2.92%
- ABBVIE INC 2.84%
- REGENERON PHARMACEUTICALS INC 2.65%
Asset Allocation
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| Stocks | 95.62% | 88.27% | 106.13% | 76.47% |
| Preferred Stocks | 3.82% | 0.00% | 7.86% | 1.96% |
| Cash | 0.40% | 0.00% | 32.01% | 81.05% |
| Bonds | 0.17% | 0.00% | 12.39% | 5.88% |
| Other | 0.00% | -22.99% | 3.18% | 88.89% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 91.89% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.84% | 71.19% | 100.00% | 85.81% |
| Basic Materials | 0.94% | 0.00% | 7.16% | 6.76% |
| Financial Services | 0.22% | 0.00% | 1.60% | 12.16% |
| Utilities | 0.00% | 0.00% | 0.00% | 91.89% |
| Technology | 0.00% | 0.00% | 2.45% | 91.89% |
| Real Estate | 0.00% | 0.00% | 5.89% | 91.89% |
| Industrials | 0.00% | 0.00% | 1.34% | 91.89% |
| Energy | 0.00% | 0.00% | 0.00% | 91.89% |
| Communication Services | 0.00% | 0.00% | 0.69% | 94.59% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 91.89% |
| Consumer Cyclical | 0.00% | 0.00% | 0.82% | 91.89% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| US | 93.52% | 61.08% | 104.41% | 57.52% |
| Non US | 2.10% | 0.00% | 36.86% | 54.90% |
Bond Sector Breakdown
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| Cash & Equivalents | 0.35% | 0.00% | 100.00% | 61.44% |
| Derivative | 0.00% | -0.01% | 0.21% | 88.89% |
| Securitized | 0.00% | 0.00% | 0.00% | 90.98% |
| Corporate | 0.00% | 0.00% | 81.57% | 92.48% |
| Municipal | 0.00% | 0.00% | 0.00% | 90.98% |
| Government | 0.00% | 0.00% | 29.44% | 90.98% |
Bond Geographic Breakdown
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| US | 0.17% | 0.00% | 11.75% | 5.88% |
| Non US | 0.00% | 0.00% | 3.33% | 92.16% |
PRHSX - Expenses
Operational Fees
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.68% | 0.08% | 4.23% | 77.12% |
| Management Fee | 0.63% | 0.03% | 1.25% | 40.52% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | 4.17% |
| Administrative Fee | 0.15% | 0.03% | 0.25% | 66.67% |
Sales Fees
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | N/A | N/A | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 33.80% | 1.00% | 238.00% | 32.82% |
PRHSX - Distributions
Dividend Yield Analysis
| PRHSX | Category Low | Category High | PRHSX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.12% | 0.00% | 6.24% | 97.39% |
Dividend Distribution Analysis
| PRHSX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
| PRHSX | Category Low | Category High | PRHSX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.21% | -2.27% | 1.85% | 50.00% |
Capital Gain Distribution Analysis
| PRHSX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 15, 2025 | $0.107 | OrdinaryDividend |
| Dec 15, 2025 | $9.995 | CapitalGainLongTerm |
| Dec 16, 2024 | $10.250 | OrdinaryDividend |
| Dec 16, 2024 | $0.008 | OrdinaryDividend |
| Dec 16, 2024 | $10.242 | CapitalGainLongTerm |
| Dec 15, 2023 | $4.578 | CapitalGainLongTerm |
| Dec 15, 2022 | $0.005 | CapitalGainShortTerm |
| Dec 15, 2022 | $1.582 | CapitalGainLongTerm |
| Dec 15, 2021 | $7.760 | OrdinaryDividend |
| Dec 15, 2020 | $7.080 | OrdinaryDividend |
| Dec 16, 2019 | $0.050 | OrdinaryDividend |
| Dec 16, 2019 | $0.080 | CapitalGainShortTerm |
| Dec 16, 2019 | $4.900 | CapitalGainLongTerm |
| Dec 14, 2018 | $0.360 | CapitalGainShortTerm |
| Dec 14, 2018 | $4.040 | CapitalGainLongTerm |
| Dec 15, 2017 | $0.950 | CapitalGainShortTerm |
| Dec 15, 2017 | $4.280 | CapitalGainLongTerm |
| Dec 15, 2016 | $0.300 | CapitalGainShortTerm |
| Dec 15, 2016 | $2.390 | CapitalGainLongTerm |
| Dec 15, 2015 | $1.550 | CapitalGainShortTerm |
| Dec 15, 2015 | $6.260 | CapitalGainLongTerm |
| Dec 15, 2014 | $1.000 | CapitalGainShortTerm |
| Dec 15, 2014 | $7.100 | CapitalGainLongTerm |
| Dec 16, 2013 | $0.900 | CapitalGainShortTerm |
| Dec 16, 2013 | $3.530 | CapitalGainLongTerm |
| Dec 17, 2012 | $0.390 | CapitalGainShortTerm |
| Dec 17, 2012 | $1.280 | CapitalGainLongTerm |
| Dec 17, 2012 | $0.140 | OrdinaryDividend |
| Dec 15, 2011 | $0.290 | CapitalGainShortTerm |
| Dec 15, 2011 | $0.670 | CapitalGainLongTerm |
| Dec 15, 2010 | $0.160 | CapitalGainLongTerm |
| Dec 15, 2008 | $0.220 | CapitalGainShortTerm |
| Dec 15, 2008 | $0.120 | CapitalGainLongTerm |
| Dec 18, 2007 | $0.900 | CapitalGainShortTerm |
| Dec 18, 2007 | $1.780 | CapitalGainLongTerm |
| Dec 19, 2006 | $0.530 | CapitalGainShortTerm |
| Dec 19, 2006 | $0.810 | CapitalGainLongTerm |
| Dec 13, 2005 | $0.160 | CapitalGainShortTerm |
| Dec 13, 2005 | $1.000 | CapitalGainLongTerm |
| Dec 12, 2001 | $0.240 | CapitalGainShortTerm |
| Dec 12, 2001 | $0.070 | CapitalGainLongTerm |
| Dec 16, 1998 | $0.220 | CapitalGainShortTerm |
| Dec 16, 1998 | $0.440 | CapitalGainLongTerm |
| Dec 26, 1997 | $0.870 | CapitalGainShortTerm |
| Dec 26, 1997 | $0.100 | CapitalGainLongTerm |
| Dec 27, 1996 | $0.400 | OrdinaryDividend |
PRHSX - Fund Manager Analysis
Managers
Ziad Bakri
Start Date
Tenure
Tenure Rank
Apr 01, 2016
6.17
6.2%
Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 8.03 | 0.25 |